Pfizer reports "52.4% efficacy" for single dose but that includes the first seven days, before things kick in, when most new infections happened. At 10-12 days, the chart (eyeballing, no underlying data yet) looks ~80-85% efficacy. Unpleasant trade-off but reality is unpleasant.
I absolutely would. I see the case for accepting only people under 55, no major comorbidities etc. till we know more.
-
-
This Tweet is unavailable.
-
This is why a major state: The fraction of supply that needs to be diverted is very low. And an IRB would approve this in a nanosecond: it is far less problematic really than the classic double-blind placebo only, since there is already a huge benefit.
- Show replies
-
Loading seems to be taking a while.
Twitter may be over capacity or experiencing a momentary hiccup. Try again or visit Twitter Status for more information.